Key result
Fantom sirolimus-eluting scaffold yields 0% device-oriented composite endpoints at 6 months in STEMI patients.
Why the study?
The study was conducted to evaluate the safety and efficacy of the Fantom bioresorbable scaffold 6 months after implantation using optical coherence tomography imaging in STEMI patients.
Observational (n=20)
No
In a small pilot study of STEMI patients, the third-generation Fantom bioresorbable scaffold demonstrated safety with no device-oriented composite endpoints or scaffold thrombosis at 6 months, alongside favorable strut coverage and healing on OCT.
Answers are grounded in this paper and cite their sources.
Should not yet change STEMI practice; hypothesis-generating for larger randomized scaffold trials.
PURPOSE: The aim of this study was to evaluate the safety and efficacy of the Fantom BRS 6 months after implantation using the optical coherence tomography (OCT) imaging. METHODS: Twenty STEMI patients treated with a sirolimus-eluting Fantom BRS were enrolled into a prospective, single-arm, serial observational study. The scaffold sizing, positioning and optimisation were guided by OCT imaging. The primary endpoint was device-orientated composite endpoints (DOCE), comprised of cardiac death, target-vessel-related myocardial infarction and target lesion failure. To evaluate the device performance at the scaffold level, we performed a quantitative coronary angiography (QCA) and OCT imaging at 6 months. RESULTS: The primary endpoint did not occur in any patient within the 6-month follow-up. There were no major adverse cardiac events (MACEs) or DOCEs, no cases of scaffold thrombosis, target lesion revascularization and no deaths. In QCA, we observed a decrease in the minimum and mean lumen diameter in the in-scaffold region and in the proximal and distal peri-scaffold region. Similarly, the minimum lumen area and reference vessel diameter had decreased in both QCA and OCT. The OCT imaging showed improvement in the expansion index and malposition rate. CONCLUSION: A serial 6-month OCT imaging after implantation of a third-generation Tyrocore-based bioresorbable coronary scaffold indicated good coverage of the struts with excellent healing of the scaffold, low neointima growth and no signs of neoatherosclerosis.
No takes yet. Share an insight, caveat, or question.
Kołtowski et al. (2023) conducted an observational in ST-Segment Elevation Myocardial Infarction (STEMI) (n=20). Fantom Encore bioresorbable scaffold (BRS) was evaluated on Device-orientated composite endpoints (DOCE) including cardiac death, target-vessel MI, or ischemia-driven TLR at 180 days. Implantation of the Fantom sirolimus-eluting bioresorbable scaffold in STEMI patients was safe, with 0% incidence of device-orientated composite endpoints at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: